Breast cancer drug showdown: which CDK4/6 inhibitor works best?
Disease control
Terminated
This phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…
Phase: PHASE3 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC